Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price Today
Aura AI Summary
Key Stats
- $39.89BMarket Cap
- -Volume
- HealthSector
- $491.2252W High
- $278.0952W Low
- -Typical Hold Time
- $38.15BEnterprise Value
- -Div Yield
- -Trading Activity
Track Alnylam Pharmaceuticals, Inc. (ALNY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Alnylam Pharmaceuticals, Inc. has traded between a low of $278.09 and a high of $491.22, highlighting its annual price range. Buy and sell Alnylam Pharmaceuticals, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Most Recent News
Uber expands beyond rides and delivery into travel, financial services, and autonomous vehicle data.
Uber is broadening its services beyond ride-hailing and food delivery to include hotel bookings, boat rentals, and shopping features, aiming to become a travel-focused platform. It is also developing financial products for drivers and merchants, such...

Mesoblast completes treatment of 300 patients in Phase 3 trial for chronic low back pain therapy.
Mesoblast has reached its goal of treating 300 patients in its pivotal Phase 3 trial of rexlemestrocel-L, a cell therapy for chronic low back pain caused by degenerative disc disease. This trial aims to confirm pain reduction benefits seen in earlier...

US Department of War suspends costly CMMC Phase II cybersecurity rules for small defense contractors.
The U.S. Department of War has suspended the Cybersecurity Maturity Model Certification (CMMC) Phase II requirements originally set for November 2026, following concerns from small defense contractors about high compliance costs and bureaucratic burd...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.